<?xml version="1.0" encoding="UTF-8"?>
<p id="Par38">The endocannabinoid system and cannabinoids have started to get more and more considerable interests for therapeutic claims (Ryan et al. 
 <xref ref-type="bibr" rid="CR114">2009</xref>) which could be observed by varieties of biological activities (Marcu 
 <xref ref-type="bibr" rid="CR76">2016</xref>). Cannabis and cannabinoids can play the role of anti-nociceptive, anti-inflammatory, immunosuppressant anti-emetogenic activity, and anticonvulsant activity (Mensah and Adu-Gyamfi 
 <xref ref-type="bibr" rid="CR79">2019</xref>). Cannabidiol (CBD) has been identified as therapeutic in human laboratory studies and clinical trials for epilepsy, anxiety, pain/inflammation, schizophrenia, various substance use disorders, post-traumatic stress disorder, and others (Sholler et al. 
 <xref ref-type="bibr" rid="CR122">2020</xref>). Furthermore, the usage of Cannabis for therapeutic purposes reported not to increase risk of harm to self or others (Walsh et al. 
 <xref ref-type="bibr" rid="CR135">2017</xref>), and the UN Commission on Narcotic Drugs already removed Cannabis and Cannabis resin from a category of the world's most dangerous substances (CND 2020; 
 <ext-link ext-link-type="uri" xlink:href="http://news.un.org/en/story/2020/12/1079132" xmlns:xlink="http://www.w3.org/1999/xlink">news.un.org/en/story/2020/12/1079132</ext-link>). Already, 33 states in the USA and several countries in the world have been using Cannabis for specific medical conditions (Sarma et al. 
 <xref ref-type="bibr" rid="CR118">2020</xref>). In June 2018, the US Food and Drug Administration (FDA) approved the first cannabis-derived medicine, EpidiolexÂ® (cannabidiol, CBD), for the treatment of seizure disorders (Abu-Sawwa et al. 
 <xref ref-type="bibr" rid="CR1">2020</xref>).
</p>
